1. GPCR/G Protein Neuronal Signaling Apoptosis Metabolic Enzyme/Protease
  2. Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor
  3. Esmolol hydrochloride

Esmolol hydrochloride  (Synonyms: 盐酸艾司洛尔)

目录号: HY-B1392 纯度: 99.92%
COA 产品使用指南 技术支持

Esmolol hydrochloride 是一种超短效心脏选择性 β1-肾上腺素 (β1-adrenergic) 能阻滞剂。Esmolol hydrochloride 通过激活 NK1 受体 (Neurokinin 1 Receptoraldose reductase)、晚期糖基化终产物的产生和促进成纤维细胞的迁移改善糖尿病的伤口愈合。Esmolol hydrochloride 可用于研究心律失常等心脏疾病以及糖尿病足溃疡。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Esmolol hydrochloride

Esmolol hydrochloride Chemical Structure

CAS No. : 81161-17-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
Free Sample (0.1 - 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ¥605
In-stock
5 mg ¥343
In-stock
10 mg ¥550
In-stock
50 mg ¥760
In-stock
100 mg ¥1100
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Esmolol hydrochloride:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers[1][2][3].

IC50 & Target[1][2][3]

β-adrenoceptor

 

Caspase 3

 

体外研究
(In Vitro)

Esmolol hydrochloride (0-1 mM) 可抑制醛糖还原酶活性,IC50 估计值为 150 µM,并可抑制红细胞中 59% 的山梨醇形成[1]
Esmolol hydrochloride (0.5-1 mM,10 分钟) 可抑制晚期糖基化终产物 (AGEs) 的形成[1]
Esmolol hydrochloride (0.01- 1000 μM,8-48 小时) 可促进 HFF-1、Ea.hy926 和 HaCaT 细胞的迁移能力,且无细胞毒性[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay [1]

Cell Line: HFF-1, Ea.hy926, HaCaT cells
Concentration: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 50 μM, 100 μM, 500 μM, 100 μM
Incubation Time: 8 h, 14 h, 16 h, 22 h, 24 h, 42 h, 48 h
Result: Promoted the ability to migrate, with low migration at 100 and 500 µM.
体内研究
(In Vivo)

Esmolol hydrochloride (7%-20%,局部涂抹,每日两次) 可改善 Streptozotocin (HY-13753) 诱发的糖尿病无毛大鼠的 NO 诱导、胶原周转和羟脯氨酸水平,并改善其重塑和伤口愈合[1]
Esmolol (10 mg/kg,0.3 mL,静脉注射,一次) hydrochloride 在永久性冠状动脉闭塞 (CAO) 大鼠模型中,通过上调 NK1 受体表现出抗心律失常作用[2]
Esmolol (300 μg/kg,肾上腺素 20 μg/kg,静脉注射,一次) hydrochloride 在近交系五指山小型猪中通过减少凋亡来保护心肌组织,改善复苏后心肌功能障碍[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Streptozotocin-induced (35 mg/kg/day for 5 consecutive days) diabetic hairless rats model[1]
Dosage: 7, 14, and 20%
Administration: topical applied, twice daily
Result: Increased the total nitrite content and NO level in wound tissue by 44% and 112% in the G14 group compared with the diabetic control group and the vehicle control group, and by 8% and 59% in the G20 group compared with the diabetic control group and the vehicle control group.
Improved collagen content, hydroxyproline levels, increased hydroxyproline levels by 22% and 44% in the G14 group, and 21% and 43% in the G20 on day 7; increased hydroxyproline levels by 6% and 13% in the G14 group, increased hydroxyproline levels by 41% and 49% in the G20 group on day 14, compared with the diabetic control and vehicle control groups.
Improved healing in G20 group and closer to normal intact diabetic skin (wounds were not completely closed on day 19) .
Animal Model: CAO male SD rats (weighing 260-280 g) model[2]
Dosage: 10 mg/kg, in 0.3 mL
Administration: i.v., once
Result: Reduced ventricular ectopic beat (VEB) by 66%, and reduced the incidence, number, and duration of VT and VF by 66%, 92%, and 95%, respectively .
Attenuated the arrhythmogenic effects of D-SP, reducing the VEB by 45%, the morbidity rate, the episodes and the durations of VT & VF by 86%, 62% and 50% respectively, in 9-23 min following the coronary artery occlusion (CAO) (14 min-28 min after the injection of esmolol).
Increased NK1-R mRNA and protein, by 72% and 19% respectively, at 15 min after the CAO.
Animal Model: Inbred wuzhishan miniature pigs (12-14 months of age, 30 kg) model[3]
Dosage: 300 μg/kg with Epinephrine (HY-B0447B) 20 μg/kg
Administration: i.v., once
Result: Reduced the number of shocks, defibrillation energy, return of spontaneous circulation (ROSC) time and 4 h heart rate (HR), and increased the 24 h survival rate, 4-6 h CO values, 4 h mean aortic pressure (MAP) value, and 4 h left ventricular dp/dtmax.
Reduced serum cTnI, lactate concentrations and , myocardial malondialdehyde (MDA) content, increased ATPase and SOD levels.
Reduced caspase-3 proteolytic activation, mRNA levels, and TUNEL-positive cells, and attenuated apoptotic effects by upregulating Bcl-2/Bax protein levels.
Clinical Trial
分子量

331.83

Formula

C16H26ClNO4

CAS 号
性状

固体

颜色

White to off-white

中文名称

盐酸艾司洛尔

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
细胞实验: 

DMSO 中的溶解度 : ≥ 100 mg/mL (301.36 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : ≥ 50 mg/mL (150.68 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0136 mL 15.0680 mL 30.1359 mL
5 mM 0.6027 mL 3.0136 mL 6.0272 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.75 mg/mL (8.29 mM); 澄清溶液

    此方案可获得 ≥ 2.75 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.75 mg/mL (8.29 mM); 澄清溶液

    此方案可获得 ≥ 2.75 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

  • 方案 一

    请依序添加每种溶剂: PBS

    Solubility: 100 mg/mL (301.36 mM); 澄清溶液; 超声助溶

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
您所需的储备液浓度超过该产品的实测溶解度,如有需要,请与 MCE 中国技术支持联系。
纯度 & 产品资料
参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.0136 mL 15.0680 mL 30.1359 mL 75.3398 mL
5 mM 0.6027 mL 3.0136 mL 6.0272 mL 15.0680 mL
10 mM 0.3014 mL 1.5068 mL 3.0136 mL 7.5340 mL
15 mM 0.2009 mL 1.0045 mL 2.0091 mL 5.0227 mL
20 mM 0.1507 mL 0.7534 mL 1.5068 mL 3.7670 mL
25 mM 0.1205 mL 0.6027 mL 1.2054 mL 3.0136 mL
30 mM 0.1005 mL 0.5023 mL 1.0045 mL 2.5113 mL
40 mM 0.0753 mL 0.3767 mL 0.7534 mL 1.8835 mL
50 mM 0.0603 mL 0.3014 mL 0.6027 mL 1.5068 mL
60 mM 0.0502 mL 0.2511 mL 0.5023 mL 1.2557 mL
80 mM 0.0377 mL 0.1883 mL 0.3767 mL 0.9417 mL
100 mM 0.0301 mL 0.1507 mL 0.3014 mL 0.7534 mL

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Esmolol hydrochloride
目录号:
HY-B1392
需求量: